SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS
Healthcare formulations, including, inventive surfactants, Active ingredient formulated as solids, liquids, or emulsions. The present disclosure provides formulations of healthcare products, such as: prescription drugs, over the counter drugs; minerals, herbal, and/or vitamin supplements; drugs administered in hospitals, clinics, physician's office, and places of palliative care; vaccines, tissue, organ, and cell transplants and/or grafts and/or infusions; and wound care formulations including topical ointments, lotions, cleaners, wipes, bandages, and dressings. The Active may be included in the formulations as a solute, a solvent, a particle, or an oil immiscible component of the formulation. The Active may be included in tablets, capsules, tinctures, liquids, or emulsions. Inventive healthcare formulations include formulations suitable for administration orally, topically, and/or by injection.
1 . A solid healthcare formulation, comprising:
at least one surfactant of Formula I:
wherein R 1 and R 2 are the same or different, and comprise at least one group selected from the group consisting of C 1 -C 6 alkyl, optionally the C 1 -C 6 alkyl may include one or more of oxygen, nitrogen, or sulfur atoms or groups that include at least one of these atoms, and the alkyl chain may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;
R 3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxy alkyl ether, alkyl phosphate, C 3 -C 8 carboxylic acid, C 1 -C 10 alkyl benzoic acid, and a C 1 -C 6 linker attached to a second molecule of Formula I, wherein the second molecule is the same or different;
n is an integer from 1 to 12;
X is selected from the group consisting of chloride, bromide, and iodide; and
at least one Active ingredient.
2 . The formulation according to claim 1 , wherein the at least one Active is selected from the group consisting of: a drug, a protein, a cell, a tissue, a vitamin, a supplement, and a mineral.
3 . The formulation according to claim 1 , further including at one or more excipients.
4 . The formulation according to claim 3 , wherein the one or more excipients are selected from the group consisting of: binders, fillers, disintegrents, salts, colorants, sweeteners, and flavorants.
5 . The formulations according to claim 1 , wherein the formulation is configured as a powder, a tablet, or a capsule.
6 . A liquid formulation for healthcare, comprising at least one surfactant of Formula I:
wherein R 1 and R 2 are the same or different, and comprise at least one group selected from the group consisting of C 1 -C 6 alkyl, optionally the C 1 -C 6 alkyl may include one or more of oxygen, nitrogen, or sulfur atoms or groups that include at least one of these atoms, and the alkyl chain may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;
R 3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxy alkyl ether, alkyl phosphate, C 3 -C 8 carboxylic acid, C 1 -C 10 alkyl benzoic acid, and a C 1 -C 6 linker attached to a second molecule of Formula I, wherein the second molecule is the same or different;
n is an integer from 1 to 12;
X is selected from the group consisting of chloride, bromide, and iodide;
at least one Active ingredient; and
an aqueous component.
7 . The formulation according to claim 6 , further including a buffer.
8 . The formulation according to claim 6 , further including one or more of the following: a sweetener, a flavorant, a colorant, and/or a preservative.
9 . The formulation according to claim 6 , further including a thickener.
10 . The formulation according to claim 9 , wherein the formulation is one of the following; a drop, a paste, a salve, a lotion, or an ointment.
11 . An emulsion for healthcare, comprising: at least one surfactant of Formula I:
wherein R 1 and R 2 are the same or different, and comprise at least one group selected from the group consisting of C 1 -C 6 alkyl, optionally the C 1 -C 6 alkyl may include one or more of oxygen, nitrogen, or sulfur atoms or groups that include at least one of these atoms, and the alkyl chain may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;
R 3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxy alkyl ether, alkyl phosphate, C 3 -C 8 carboxylic acid, C 1 -C 10 alkyl benzoic acid, and a C 1 -C 6 linker attached to a second molecule of Formula I, wherein the second molecule is the same or different;
n is an integer from 1 to 12; and
X is selected from the group consisting of chloride, bromide, and iodide, at least one Active ingredient;
an aqueous phase; and
a non-aqueous phase.
12 . The emulsion of claim 11 , further including a buffer.
13 . The emulsion of claim 11 , further including one or more of the following: a sweetener, a flavorant, a colorant, and/or a preservative.
14 . A method of preparing the healthcare formulation of claim 1 comprising:
synthesizing a compound of Formula I
wherein R 1 and R 2 are the same or different, and comprise at least one group selected from the group consisting of C 1 -C 6 alkyl, optionally the C 1 -C 6 alkyl may include one or more of oxygen, nitrogen, or sulfur atoms or groups that include at least one of these atoms, and the alkyl chain may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate; R 3 is selected from the group consisting of alkenyl, alkynyl, ester, alcohol, aryl alkyl, alkoxy alkyl ether, alkyl phosphate, C 3 -C 8 carboxylic acid, C 1 -C 10 alkyl benzoic acid, and a C 1 -C 6 linker attached to a second molecule of Formula I, wherein the second molecule is the same or different; n is an integer from 1 to 12; and X is selected from the group consisting of chloride, bromide, and iodide, the method comprising: a ring opening step to open lactam ring to provide an amino acid having an N-terminus and a C-terminus; a first alkylation step, to alkylate the N-terminus to provide a tertiary amine; a coupling step, to react the C-terminus with 3-aminopropyltris(trimethylsiloxy)silane to provide siloxane derivative; and a second alkylation step, to alkylate the N-terminus to provide a quaternary amine of Formula I, and
adding at least one active ingredient selected from the group consisting of: a drug, a protein, a cell, a tissue, a vitamin, a supplement, and a mineral, and optionally an excipient.
15 . The method of claim 14 , wherein the lactam is caprolactam.
16 . The method of claim 14 , wherein in the first alkylation step, the tertiary amine is 6-(dimethylamino)hexanoic acid.
17 . The method of claim 14 , wherein in the second alkylation step, the N-terminus is alkylated with an alkylating agent selected from the group consisting of benzyl bromide, ethyl bromoacetate, allyl iodide, propargyl bromide, 1-bromo-2-(2-methoxyethoxy)ethane, bromo phosphonate, 3-iodopropanol, 3-bromopropanol, 2-iodoethanol, 2-bromoethanol, 6-bromohexanoic acid, and 1,3-dibromopropane.